The ?Neuromyelitis Optica Spectrum Disorder (2nd Edition): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031? report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of neuromyelitis optica spectrum disorder.
Creech Holland
Lucas Townsend
Hollis Ingram
Ewing Ware
Ramirez Robertson
Bay Field
Weber Larkin
Gustafson Reynolds
Duncan Burch
Grant Cherry